MedTrace Logo

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

NCT06297369 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-07

No results posted yet for this study

Summary

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

Conditions

  • Cisplatin Adverse Reaction
  • Cisplatin Nephrotoxicity
  • Cisplatin Induced Peripheral Neuropathy
  • Cancer Patients
  • Cisplatin Ototoxicity

Interventions

DRUG

N acetyl cysteine

N-acetylcysteine 600 mg twice daily (acetylcystein ® 600 mg effervescent instant granules sachets, Sedico, Egypt)

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • mahmoud ibrahim · Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2025-02-01
Completion
2025-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06297369 on ClinicalTrials.gov